Assessing the effect of HAART on change in quality of life among HIV-infected women

被引：54

作者：

Liu C. ^{[1
,2
]}

Weber K. ^{[3
]}

Robison E. ^{[4
]}

Hu Z. ^{[1
]}

Jacobson L.P. ^{[1
]}

Gange S.J. ^{[1
]}

机构：

[1] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

[2] Department of Medicine, Georgetown University School of Medicine, Washington, DC

[3] The CORE Center, John H. Stroger Jr Hospital of Cook County, Chicago, IL

[4] Montefiore Medical Center, New York, NY

来源：

AIDS Research and Therapy | / 3卷 / 1期

关键词：

Propensity Score; Propensity Score Match; Propensity Score Method; Background Covariates; Pattern Mixture Model;

D O I：

10.1186/1742-6405-3-6

中图分类号：

学科分类号：

摘要：

Background: The impact of highly active antiretroviral therapy (HAART) on health-related quality of life (QOL) of HIV-I infected individuals in large prospective cohorts has not been well studied. Objective: To assess the effect of HAART on QOL by comparing HIV-infected women using HAART with HIV-infected women remaining HAART naïve in the Women's Interagency HIV Study (WIHS), a multicenter prospective cohort study begun in 1994 in the US. Methods: A 1:1 matching with equivalent (≤ 0.1%) propensity scores for predicting HAART initiation was implemented and 458 pairs were obtained. HAART effects were assessed using pattern mixture models. The changes of nine QOL domain scores and one summary score derived from a shortened version of the MOS-HIV from initial values were used as study outcomes. Results: The background covariates of the treatment groups were well-balanced after propensity score matching. The 916 matched subjects had a mean age of 38.5 years and 42% had a history of AIDS diagnosis. The participants contributed a total of 4,292 person visits with a median follow-up time of 4 years. In the bivariate analyses with only HAART use and time as covariates, HAART was associated with short-term improvements of 4 QOL domains: role functioning, social functioning, pain and perceived health index. After adjusting for demographic, socioeconomic, biological and clinical variables, HAART had small but significant short-term improvements on changes in summary QOL (mean change: 3.25; P = 0.02), role functioning (6.99; P < 0.0 1), social functioning (5.74; P < 0.01), cognitive functioning (3.59; P = 0.03), pain (6.73; P < 0.01), health perception (3.67; P = 0.03) and perceived health index (4.87; P < 0.01). These QOL scores typically remained stable or declined over additional follow-up and there was no indication that HAART modified these trends. Conclusion: Our study demonstrated significant short-term HAART effects on most QOL domains, but additional use of HAART did not modify long-term trends. These changes could be attributed to the direct effect of HAART and indirect HAART effect mediated through clinical changes. © 2006 Liu et al; licensee BioMed Central Ltd.

引用

共 32 条

[1]

Hays R.D., Cunningham W.E., Sherbourne C.D., Wilson I.B., Wu A.W., Cleary P.D., McCaffrey D.F., Fleishman J.A., Crystal S., Collins R., Eggan F., Shapiro M.F., Bozzette S.A., Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study, Am J Med, 108, 9, pp. 714-722, (2000)

[2]

Detels R., Munoz A., McFarlane G., Kingsley L.A., Margolick J.B., Giorgi J., Schrager L.K., Phair J.P., Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration, Jama, 280, 17, pp. 1497-1503, (1998)

[3]

Gange S.J., Barron Y., Greenblatt R.M., Anastos K., Minkoff H., Young M., Kovacs A., Cohen M., Meyer W.A., Munoz A., Effectiveness of highly active antiretroviral therapy among HIV-I infected women, J Epidemiol Community Health, 56, 2, pp. 153-159, (2002)

[4]

Palella F.J.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, 338, 13, pp. 853-860, (1998)

[5]

Carrieri P., Spire B., Duran S., Katlama C., Peyramond D., Francois C., Chene G., Lang J.M., Moatti J.P., Leport C., Health-related quality of life after 1 year of highly active antiretroviral therapy, J Acquir Immune Defic Syndr, 32, 1, pp. 38-47, (2003)

[6]

Nieuwkerk P.T., Gisolf E.H., Colebunders R., Wu A.W., Danner S.A., Sprangers M.A., Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy, Aids, 14, 2, pp. 181-187, (2000)

[7]

Gill C.J., Griffith J.L., Jacobson D., Skinner S., Gorbach S.L., Wilson I.B., Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life, J Acquir Immune Defic Syndr, 30, 5, pp. 485-492, (2002)

[8]

Zinkernagel C., Ledergerber B., Battegay M., Cone R.W., Vernazza P., Hirschel B., Opravil M., Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study, Aids, 13, 12, pp. 1587-1589, (1999)

[9]

Chan K.S., Orlando M., Ghosh-Dastidar B., Duan N., Sherbourne C.D., The interview mode effect on the Center for Epidemiological Studies Depression (CES-D) scale: An item response theory analysis, Med Care, 42, 3, pp. 281-289, (2004)

[10]

Low-Beer S., Chan K., Wood E., Yip B., Montaner J.S., O'Shaughnessy M.V., Hogg R.S., Health related quality of life among persons with HIV after the use of protease inhibitors, Qual Life Res, 9, 8, pp. 941-949, (2000)

← 1 2 3 4 →